作者
Idanna Innocenti, Antonio Mosca, Annamaria Tomasso, Andrea Galitzia, Lydia Scarfò, Eugenio Galli, Roberta Laureana, Giulia Benintende, Veronica Mattiello, Francesca Morelli, Sabrina Chiriu, Maria Ilaria Del Principe, Giulia Zamprogna, Massimo Gentile, Nicole Fabbri, Francesco Autore, Paolo Sportoletti, Alberto Fresa, Gioacchino Catania, Marta Coscia, Alessandra Tedeschi, Alessandro Sanna, Marzia Varettoni, Paolo Ghia, Roberta Murru, Luca Laurenti
发表日期
2023/8/1
期刊
HemaSphere
卷号
7
期号
S3
页码范围
e83737e4
出版商
LWW
简介
Background: Increased absolute lymphocyte count (ALC) characterizes chronic lymphocytic leukemia (CLL), and it is also observed in the first phase of treatment with Ibrutinib (IBR), the “first-in-class” Bruton’s tyrosine kinase inhibitor (BTKi), independently of previous lines of treatment. The IBR induced lymphocytosis, which is due to a redistribution of lymphocytes from the neoplastic nodal compartment into the peripheral blood, is observed in 57% of patients treated in first line, and it is higher in IgHV mutated CLL. Prolonged lymphocytosis likely represents the persistence of a quiescent clone. This phenomenon is transient in most patients, resolving within 8 months, but can rarely persist over 12 months, without impact on survival. Despite lymphocytosis in IBR has been widely investigated, little is known about the presence and duration of lymphocytosis in patients treated with Acalabrutinib (Acala).
Aims: The main …
学术搜索中的文章
I Innocenti, A Mosca, A Tomasso, A Galitzia, L Scarfò… - HemaSphere, 2023